CT-P10 (Truxima™): A Rituximab Biosimilar.

Area of Science:

• Immunology
• Oncology
• Rheumatology

Background:

• Rituximab, a monoclonal anti-CD20 antibody, is a well-established therapy for various cancers and autoimmune conditions.
• The development of biosimilars offers potential for increased patient access to effective treatments.

Purpose of the Study:

• To evaluate CT-P10 (Truxima™), the first rituximab biosimilar, for its efficacy, safety, and tolerability.
• To confirm the biosimilarity of CT-P10 to reference rituximab across multiple indications.

Main Methods:

• Physicochemical and pharmacodynamic characterization of CT-P10 compared to reference rituximab.
• Pharmacokinetic studies in patients with rheumatoid arthritis (RA) or follicular lymphoma (FL).
• Clinical trials assessing efficacy and safety in patients with RA and FL.

Main Results:

• CT-P10 exhibited similar physicochemical and pharmacodynamic properties to reference rituximab.
• Pharmacokinetic biosimilarity was demonstrated in patients with RA or FL.
• CT-P10 showed equivalent clinical efficacy and comparable safety, tolerability, and immunogenicity profiles to reference rituximab in RA patients.
• Switching from reference rituximab to CT-P10 did not impact safety or efficacy.

Conclusions:

• CT-P10 is a safe and effective biosimilar to rituximab, suitable for all approved indications.
• CT-P10 provides a valuable therapeutic option for patients requiring anti-CD20 antibody treatment.
• The established role of rituximab in managing autoimmune diseases and cancers is complemented by the availability of CT-P10.